Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade... Show more
APLS saw its Momentum Indicator move above the 0 level on November 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for APLS just turned positive on November 24, 2025. Looking at past instances where APLS's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
APLS moved above its 50-day moving average on December 05, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APLS advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 186 cases where APLS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for APLS crossed bearishly below the 50-day moving average on November 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
APLS broke above its upper Bollinger Band on December 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.874) is normal, around the industry mean (28.362). P/E Ratio (69.347) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (3.154) is also within normal values, averaging (336.196).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MYIMX | 25.38 | 0.21 | +0.83% |
| Victory Integrity Mid-Cap Value Y | |||
| LZUSX | 18.92 | 0.10 | +0.53% |
| Lazard US Equity Focus Instl | |||
| APDJX | 19.42 | 0.03 | +0.15% |
| Artisan International Small-Mid Advisor | |||
| STDFX | 48.00 | N/A | N/A |
| Allspring Large Cap Growth Admin | |||
| RRMGX | 85.97 | -5.35 | -5.86% |
| T. Rowe Price Mid-Cap Growth R | |||
A.I.dvisor indicates that over the last year, APLS has been loosely correlated with IMVT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To APLS | 1D Price Change % | ||
|---|---|---|---|---|
| APLS | 100% | +1.15% | ||
| IMVT - APLS | 39% Loosely correlated | +5.31% | ||
| VNDA - APLS | 39% Loosely correlated | -2.22% | ||
| MRSN - APLS | 38% Loosely correlated | +0.43% | ||
| NUVL - APLS | 37% Loosely correlated | +0.16% | ||
| DNLI - APLS | 37% Loosely correlated | -1.14% | ||
More | ||||